# BPC-157: Research Overview — buyresearchpeptidesonline > A literature summary of BPC-157 (Body Protection Compound 157): angiogenesis mechanism, VEGFR2 signaling, pharmacokinetics, gut cytoprotection, and the state of human evidence as of 2025. A stable synthetic pentadecapeptide derived from gastric juice protein, whose tissue-repair effects in animals track most consistently with the growth of new blood vessels. ## The short version **BPC-157** stands for Body Protection Compound 157. It is a synthetic peptide fifteen amino acids long, with a sequence derived from a cytoprotective (cell-protecting) protein found in human gastric juice. In animal studies — overwhelmingly rats — it appears to accelerate healing across a range of tissues: tendons, the gut lining, muscle and more [12]. The most consistent explanation researchers offer is that it stimulates the body to grow new blood vessels into an injury site, delivering the oxygen and nutrients that repair depends on [11]. Here is what the record honestly looks like. As of 2025 reviews, only three small human pilot studies of BPC-157 exist, and there are no large, rigorous controlled human trials [9]. BPC-157 is not an approved drug anywhere. Popular online claims about weight loss, muscle building or testosterone increases are not supported by the published evidence and should be treated skeptically [9]. This page reports what was studied; it is not advice, and it lists no human dose. ## What it is BPC-157 is a stable gastric pentadecapeptide — "pentadecapeptide" simply means a peptide of fifteen amino acids, and "stable gastric" because the sequence is derived from a cytoprotective protein in gastric juice and is resistant to breakdown in the stomach environment. Its amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is catalogued under research designations including PL 14736, PLD-116, PL-10, and Bepecin. BPC-157 is a synthetic research peptide, not a natural extract, and not an approved drug by any regulatory body. In 2023, the FDA identified BPC-157 as a substance not eligible for pharmacy compounding under 503A, pending further evaluation — meaning it sits outside standard compounding channels in the United States. ## How it works The best-characterized mechanism is *angiogenesis* — the formation of new blood vessels. In a 2017 study that combined a chick chorioallantoic membrane model, a rat hindlimb ischemia model, and human vascular endothelial cell cultures, BPC-157 increased the expression of VEGFR2 (a key vessel-growth receptor) and promoted its internalization, activating the downstream VEGFR2-Akt-eNOS signaling pathway; blocking endocytosis of VEGFR2 blocked the effect. In the ischemic muscle model it accelerated blood-flow recovery into the damaged area [11]. In plain terms: BPC-157 appears to make blood-vessel cells more responsive to the body's own "grow new vessels" signaling cascade. By bringing new capillaries into a wound or damaged tissue, it creates the conditions for matrix-making cells to arrive, rebuild, and survive. Beyond angiogenesis, BPC-157 is described as a brain-gut-axis modulator: animal studies report effects on serotonin and dopamine systems, and cell-migration pathways such as FAK-paxillin have been implicated. In tendon fibroblast cultures, it appears to sensitize the growth-hormone receptor, which may amplify local growth-factor signaling. The overall picture is a peptide that engages several repair-related signals rather than a single target — which may partly explain the breadth of animal models in which effects have been reported. ## What the research shows *Foundational gut cytoprotection.* In the foundational gastric ulcer study in Wistar rats, BPC-157 reduced ulcer area and accelerated ulcer healing, with ulcer-formation inhibition ratios of roughly 46-66% at higher doses and accelerated glandular-epithelium rebuilding and granulation-tissue formation; intramuscular delivery outperformed intragastric in this model [12]. *Angiogenesis mechanism.* The 2017 VEGFR2 study established the angiogenic mechanism across three model systems, including human endothelial cells, with measurable increases in vessel density and blood-flow recovery [11]. *Pharmacokinetics.* The first formal PK/ADME characterization, in rats and beagle dogs, found linear pharmacokinetics, a very short elimination half-life (under 30 minutes), modest intramuscular bioavailability (approximately 14-19% in rats and 45-51% in dogs), and rapid breakdown into small peptide fragments that enter normal amino-acid metabolism [10]. A short half-life means the intact peptide does not remain in the bloodstream for long after a dose. *Human safety pilot.* In a 2025 first-in-human intravenous safety study, BPC-157 up to 20 mg was given to two healthy adults (a 58-year-old male and a 68-year-old female). It was well tolerated with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [8]. This was a safety pilot with two participants, not an efficacy trial — the result is reassuring but not conclusive. *State of the evidence.* A 2025 narrative review of BPC-157 for musculoskeletal healing concluded that despite broad preclinical support, human data are extremely limited (only three pilot studies), rigorous large-scale trials are lacking, and BPC-157 should be considered investigational and used with caution given regulatory controversy and its availability outside regulated channels [9]. ## Reported effects, cautions & safety The safety picture within the tiny human dataset and the animal work is reassuring as far as it goes. The operative phrase is "as far as it goes": the absence of long-term, large-sample human data means the real balance of benefit and risk in people is genuinely unknown [9]. **Reported benefits (anecdotal, not clinical evidence):** In research-use communities, people most commonly describe stubborn tendon, ligament and joint problems feeling better and more usable, sometimes within one to three weeks. Joint stiffness and painful movement ease. Gut complaints (bloating, cramping, urgency, food intolerance) improve within the first one to two weeks. Some users report cuts and scrapes closing faster. A smaller group describe better sleep or mood. These are personal accounts, not results from controlled human trials. **Reported adverse effects (anecdotal, not clinical evidence):** The most common complaint is a local reaction at the injection site — brief stinging, redness or a small raised bump, typically gone within a day. Mild nausea or stomach upset is reported in the first few days, more often with oral products than with injections. Some users feel fatigued in the first week. Mild headaches, brief dizziness after injecting, and transient flushing or warmth are occasionally reported. Persistent palpitations, chest pain or marked blood-pressure changes are treated by community commentators as reasons to stop and seek evaluation. **Literature-based cautions:** - *Overwhelmingly preclinical.* Almost all published evidence is in rodents. Only three small human pilot studies exist as of 2025 reviews, and large rigorous trials are lacking [9]. - *Single-group concentration.* A large share of the foundational literature comes from one research group; newer authors explicitly flag the limited independent replication [9]. - *Not an approved drug; unregulated supply.* BPC-157 is not approved as a medicine anywhere and moves through non-regulated channels, so the identity, purity and content of any given product are not externally verified [9]. - *Pro-angiogenic activity and theoretical cancer concern.* The same VEGFR2-driven angiogenesis tied to repair could theoretically be unhelpful for someone with an active or suspected cancer, since tumors also depend on new blood vessels. This is mechanistic reasoning, not a finding from human studies [11]. - *Possible interaction with serotonin-affecting medicines.* Animal studies show BPC-157 alters serotonin activity and has modified the course of drug-induced serotonin syndrome, raising a mechanism-based caution about concurrent use with serotonin-raising medicines such as certain antidepressants. - *Growth signaling and long-term unknowns.* In tendon cells BPC-157 increased growth-hormone-receptor signaling; any agent that nudges growth pathways carries a theoretical question about long-term effects not addressed by existing data. - *Banned in competitive sport.* BPC-157 is prohibited at all times by the World Anti-Doping Agency under the S0 (non-approved substances) category. Any athlete subject to drug testing should know this. - *Unstudied in pregnancy, breastfeeding and children.* No human data exist for these populations. ## Where it fits in collagen and matrix research Among the two peptides on this desk, BPC-157 is the angiogenesis and cytoprotection entry — the blood-supply and cell-protection side of tissue repair, rather than the matrix-construction side. Its gastric origin points to a gut-mucosal repair dimension that has no equivalent in GHK-Cu's story; its VEGFR2-driven mechanism explains why effects appear across such a diverse set of tissue models in animals [11][12]. The gap in its record — a deep, internally consistent preclinical signal with only three small human pilots [9] — is the defining limitation. It pairs with [GHK-Cu](/ghk-cu) not as a redundant molecule but as a complementary one: where GHK-Cu builds and maintains the matrix scaffold, BPC-157 is studied for restoring the vascular infrastructure the scaffold depends on. See the [comparison page](/compare) for a direct side-by-side. --- An independent literature desk — every claim tied to a citation, no products listed, no dose ever recommended.